RedHill Biopharma Ltd. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (18)

Latest Posts

About This Stock More About This Stock
The Biotech Analyst Run Down For Friday, June 12, 2019
Article By: Bret Jensen
Friday, July 12, 2019 9:00 AM EST
The biotech sector was off nearly one and a half percent in trading yesterday. Investors are waiting to hear the details of the administration’s new initiative to reduce drug prices by pegging.
In this article: FATE, RDHL, NOVN, RYTM
Read
RedHill's R&D Day Highlights Potential For Bekinda
Article By: Jason Napodano
Thursday, April 27, 2017 1:57 PM EST
RedHill Biopharma Ltd held an R&D Day highlighting for investors the clinical and commercial attributes of BEKINDA (RHB-102).
In this article: RDHL
Read
Yeliva Granted Orphan Drug Designation In Cholangiocarcinoma
Article By: Jason Napodano
Tuesday, April 4, 2017 3:58 PM EST
I ultimately believe that RedHill will look to partner Yeliva for Phase 3 development, and RedHill is certainly well-funded today with $66 million on hand as of December 2016, but every bit of financial assistance helps.
In this article: RDHL
Read
RedHill Expects Bekinda Top-Line Data In Q2
Article By: Jason Napodano
Monday, February 13, 2017 2:05 PM EST
RedHill Biopharma Ltd. announced that the final patient has been enrolled in the company's Phase 3 clinical study examining Bekinda as a treatment for acute gastroenteritis and gastritis.
In this article: RDHL
Read
MS An Interesting Upshot Opportunity For RedHill's RHB-104
Article By: Jason Napodano
Tuesday, December 13, 2016 12:14 PM EST
RedHill has numerous catalysts on the horizon that should make the next six to nine months a good time to be a shareholder, including the potential closing of a product acquisition or in-licensing in the next few weeks.
In this article: RDHL
Read

Latest Tweets for $RDHL

No tweets yet!